Blood and Organ Bank - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The blood and organ bank market size was valued at USD 36.42 billion in 2025 and is estimated to grow from USD 38.57 billion in 2026 to reach USD 52.75 billion by 2031, at a CAGR of 6.46% during the forecast period (2026-2031). This report is Segmented by Product Type (Blood, Organs), Function (Collection, Processing, Testing, Storage, Transportation), End User (Hospitals, Ambulatory Surgery Centers, Pharmaceutical Companies, Clinics and Nursing Homes, Research and Academic Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood and Organ Bank Market Trends and Insights

Rising Transplant Volume and Blood Demand: Oncology and Cell Therapy Redefine Consumption Patterns

Global transplant activity continues to rise across kidney, liver, heart, and lung procedures, and that keeps blood component demand elevated alongside organ procurement activity in the blood and organ bank market. Each transplant procedure requires red blood cells, platelets, and plasma during surgery and perioperative care, which means transplant growth adds pressure to already tight blood inventories. America’s Blood Centers reported in February 2026 that more than 25% of the U.S. blood supply is used in cancer care, which shows how oncology has become one of the largest endpoints for transfusion demand. The same release stated that U.S. hospitals transfuse red blood cells to 3.65 million patients each year, while daily use exceeds 6,000 units of platelets and 5,200 units of plasma. Cell therapy protocols are adding another layer of platelet and component use, which extends demand beyond traditional surgery and trauma settings. As transplant programs expand in more hospital systems, the blood and organ bank market is seeing stronger demand from multiple clinical pathways at the same time, and supply networks have not fully caught up with that pace.

Rising Use of Advanced Component Separation and Storage Systems: Automation Extends the Addressable Pool

Automation in blood component separation is reducing manual variability, improving yield consistency, and helping blood centers process whole blood faster in the blood and organ bank market. Terumo Blood and Cell Technologies stated in 2025 that Carter BloodCare became the first U.S. blood center to complete a full transition to automated whole blood processing with the Reveos system and Lumia software platform. That transition matters because one centrifugation cycle can separate platelets, plasma, and red blood cell concentrates, which supports higher throughput with tighter process control. On the organ side, machine perfusion continues to gain ground as a practical alternative to static cold storage for selected transplant pathways. The FDA granted a PMA supplement for TransMedics’ Organ Care System Liver on March 9, 2026, which reinforces the regulatory standing of active organ preservation systems in the United States. Taken together, automation in blood banking and active perfusion in organ preservation are widening the usable supply base, which supports the medium-term expansion of the blood and organ bank market.

Chronic Donor Shortages and High Deferral Rates: The Supply Ceiling That Technology Cannot Easily Lift

The most persistent limit on the blood and organ bank market is still the gap between eligible donors and actual donation volumes. The American Red Cross stated in January 2026 that the blood supply in the United States fell 35% in one month after flu activity and severe winter weather disrupted nearly 400 blood drives. The same release noted that while 62% of the U.S. population is eligible to give blood, only 3% donate each year. A 2025 study in Transfusion found that the shift to individual donor assessment is still in the early stages of national adoption, which means eligibility broadening has not yet offset the wider shortage pattern. A 2025 study in the Journal of Healthcare and Disease Control also showed that stricter infectious disease testing can improve safety while raising deferral pressure in endemic settings, which creates a difficult balance between safety and availability. This leaves the blood and organ bank market with a structural supply ceiling that technology can soften, but not remove, when donor participation remains weak.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Patient Blood Management Programs: Analytics Platforms Convert Savings into Systemic Adoption
• Remote-Location Organ Logistics Requiring Extended Preservation Windows: Procurement Geography Expands
• Cold-Chain Compliance Cost Burden: Infrastructure Investment Penalizes Smaller Operators Disproportionately

Segment Analysis

Blood held 63.83% of the blood and organ bank market share in 2025 and is projected to expand at 7.89% CAGR through 2031, which gives it both the largest and the fastest-growing position within product type. That combination reflects a demand base that is still broadening rather than leveling off, especially in oncology, trauma, perioperative care, and cell therapy support. America’s Blood Centers stated in February 2026 that cancer care alone uses more than 25% of the U.S. blood supply, which confirms how strongly oncology shapes blood utilization. The same dataset also recorded prehospital transfusion as a visible and growing part of blood use, which points to wider deployment outside traditional inpatient settings. AABB’s 35th edition of standards took effect in April 2026 with updated requirements for critical technology monitoring and pathogen-reduced cryoprecipitated fibrinogen complex preparation, which supports another cycle of equipment review across accredited blood centers.

Organs represented the smaller product base in 2025, but this segment remains strategically important because device, preservation, and logistics intensity are much higher per transplant event in the blood and organ bank industry. The key commercial opportunity lies in improving the use of marginal-donor organs that were historically discarded because static preservation outcomes were too uncertain. The FDA supplement for TransMedics’ Organ Care System Liver and Terumo’s October 2025 acquisition of OrganOx both show that larger medtech companies are committing capital and regulatory effort to active organ preservation. As that clinical and commercial base deepens, organ banking is likely to move further away from cold-storage defaults and closer to active perfusion across more transplant pathways in the blood and organ bank market.

Complete Report Scope:

• By Product Type
  • Blood
  • Organs
• By Function
  • Collection
  • Processing
  • Testing
  • Storage
  • Transportation
• By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Pharmaceutical Companies
  • Clinics and Nursing Homes
  • Research and Academic Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.63% of the blood and organ bank market share in 2025, which kept it in the leading regional position on the strength of accredited blood-bank networks, established organ procurement systems, and deeper device adoption. The United States remains the largest contributor within the region because it combines a large transfusion base with active investment in automation and perfusion technology. The American Red Cross shortage alert in January 2026 showed that even mature networks remain vulnerable when weather and illness disrupt donor turnout and blood-drive activity. AABB’s April 2026 standards cycle is also reinforcing a compliance-led equipment refresh across accredited operators, which supports continued spending on monitoring and process control. Canada and Mexico are expanding digital donor management and cold-chain capability, but the regional revenue base still rests mainly on U.S. system scale and procurement intensity.

Europe remains the second-largest regional market, and the region is being reshaped by Regulation (EU) 2024/1938, which replaces older directives with a more unified framework for substances of human origin. Germany, the United Kingdom, and France continue to lead on procedure volume and infrastructure depth in the blood and organ bank market. NHS Lothian’s first use of Kidney Assist Transport in May 2026 shows that machine-supported preservation is moving into routine hospital practice in parts of the region. Italy’s BILGAI partnership also shows that Europe is investing in AI-led blood supply chain management, not only in devices, which broadens the region’s role in digital infrastructure development.

The blood and organ bank market size for Asia-Pacific is projected to grow at 8.15% CAGR through 2031, making it the fastest-growing region in the global outlook. Growth is being supported by hospital capacity expansion in China, demographic pressure in Japan, and a more formal blood logistics environment in India. Middle East and Africa and South America remain smaller regional bases, but national blood strategies in the GCC and PBM-linked savings in Brazil show that operational improvement is widening beyond the largest established markets.

List of Companies Covered in this Report:

• America’s Blood Centers
• Artivion, Inc.
• Blood Centers of America
• BMI OrganBank
• Bridge to Life Ltd.
• Canadian Blood Services
• CSL Plasma
• Donate Life America
• LifeCenter Northwest
• New England Donor Services
• New York Blood Center
• NHS Blood and Transplant
• Organox
• Paragonix Technologies
• Preservation Solution
• Sanquin
• Terumo
• The American National Red Cross
• The Living Bank
• Vitalant
• Waters Medical Systems, LLC
• Xvivo Perfusion

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support